Jazz Pharmaceuticals (JAZZ) is up 20.6%, or $29.04 to $170.11.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals price target raised to $194 from $155 at RBC Capital
- Promising Phase 3 Trial Results and Expanding Indications Drive Buy Rating for Jazz Pharmaceuticals
- Jazz Pharmaceuticals price target raised to $205 from $185 at Morgan Stanley
- Jazz Pharmaceuticals rises 20.8%
- Jazz Pharmaceuticals Stock Surges on Positive Phase 3 Trial Results